{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T02:53:29Z","timestamp":1720925609611},"reference-count":30,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A high number of new drugs have entered clinical development and many of them have recently been approved for patients with lymphoid malignancies. The availability of new drugs offers additional treatment options, but it also requires particular attention for the emergence of adverse events. In addition, new drugs may also have interactions with other drugs, which could further increase the risk of toxicities or result in decreased efficacy. Here we review potential drug interactions for nonchemotherapy new drugs approved for patients with lymphoid malignancies.<\/jats:p>","DOI":"10.1002\/hon.2859","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:14:29Z","timestamp":1623248069000},"page":"78-82","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New drugs and pharmacological interactions in real life"],"prefix":"10.1002","volume":"39","author":[{"given":"Anastasios","family":"Stathis","sequence":"first","affiliation":[{"name":"New Drugs Development Unit Oncology Institute of Southern Switzerland Bellinzona Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01528-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.113.007518"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1887"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp369"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.48"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351133"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv029"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5076-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220984244"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1251592"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.060061"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong J","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.419"},{"key":"e_1_2_9_23_1","unstructured":"IMBRUVICA (Ibrutinib)\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205552s002lbl.pdf"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"e_1_2_9_25_1","unstructured":"Calquence\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf"},{"key":"e_1_2_9_26_1","unstructured":"Label\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213217s000lbl.pdf"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04137-6"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808"},{"key":"e_1_2_9_29_1","unstructured":"Aliqopa\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf"},{"key":"e_1_2_9_30_1","unstructured":"Duvelisib\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf"},{"key":"e_1_2_9_31_1","unstructured":"Venclexta\u2014FDA.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T18:17:46Z","timestamp":1699121866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/hon.2859"],"URL":"https:\/\/doi.org\/10.1002\/hon.2859","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2021-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}